Apellis Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 25, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2022-01-21

Reporting Person: Brown Victoria L. (Program Team Lead)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-21	Common Stock	A	17466	—	Acquired	29016	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-21	Stock Option (Right to Buy)	$35.46	A	24774	Acquired	2032-01-20	Common Stock (24774)	Direct

Footnotes

F1: This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.

F2: Includes 128 shares from 10/29/21 ESPP purchase.

F3: This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.